Elanco Animal Health Incorporated

Elanco Animal Health Incorporated (ELAN) Market Cap

Elanco Animal Health Incorporated has a market capitalization of $11.80B.

Price: $23.63

-1.08 (-4.37%)

Market Cap: 11.80B

NYSE · time unavailable

CEO: Jeffrey N. Simmons

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

IPO Date: 2018-09-20

Website: https://www.elanco.com

Elanco Animal Health Incorporated (ELAN) - Company Information

Market Cap: 11.80B|Sector: Healthcare

Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Analyst Sentiment

86%
Strong Buy

From 17 Active Polls

1Y Forecast: $28.67

▲ +21.3% Potential Upside

Consensus Target Metrics

Low Bound

$23

Median

$30

High Bound

$30

Average

$29

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$28.67
▲ +21.33% Upside
Low Target
$23.00
-3% Risk
Median Target
$30.00
27% Mid
High Target
$30.00
27% Max
Consensus
Buy
14 / 20 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)11,80211,91011,24510,0067,0915,1995,9877,2616,968
Enterprise Value ($M)15,36515,47314,71713,52510,7619,1079,84011,12812,228
Price to Earnings Ratio (P/E)-48.6052.24-10.19-73.57161.1719.40-187.104.99-34.84
Price/Earnings-to-Growth Ratio (PEG)2.63-16.5440.061.14
Price to Sales Ratio (P/S)2.418.699.838.805.714.365.877.055.89
Price to Book Ratio (P/B)1.811.831.721.481.050.820.981.111.17
Price to Free Cash Flow Ratio (P/FCF)37.47-313.42244.4578.7839.40-75.3448.2860.5141.98
Enterprise Value to Sales (EV/Sales)11.2912.8611.898.677.639.6510.8010.33
Enterprise Value to EBITDA (EV/EBITDA)20.3550.402452.8175.9840.7633.2456.2313.6762.71
Debt to Equity Ratio4.720.610.610.600.620.690.710.670.96

ELAN Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$23.63
Intrinsic Value$7.31
Market Alignment
Overvalued by 69.0%relative to calculated intrinsic value
9.00%
Exp: -0%-0%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)

Terminal FCF Base$0.53B
Perpetuity TV Value$9.94B
Discounted TV (PV)$4.20B
TV Weighting %57.4%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 ELANCO ANIMAL HEALTH INC (ELAN) — Investment Overview

🧩 Business Model Overview

Elanco develops, manufactures, and commercializes animal health products sold to veterinary channels and animal producers. The value chain runs from R&D and regulatory approval (for safety and efficacy) through manufacturing and quality systems to distribution via wholesalers, direct-to-vet coverage, and farm/account programs.

Customer stickiness is supported by the practical “formulary” workflow common in veterinary medicine: veterinarians and production managers build treatment protocols based on product effectiveness, label claims, ease of administration, and prior outcomes. Switching typically requires re-education, re-validation of outcomes in the field, and—at the livestock level—changes to herd management routines. Elanco’s portfolio coverage across species (livestock and companion) further supports adoption through cross-selling across multiple need states (parasite control, respiratory health, etc.).

💰 Revenue Streams & Monetisation Model

Elanco’s monetization is dominated by product sales, with revenue tied to both volume and realized pricing in end markets such as swine, cattle, poultry (where applicable by portfolio), and companion animals. The model is largely transactional at the point of sale, but it can exhibit quasi-recurring behavior through repeat use of therapeutic and preventive regimens.

Primary margin drivers include (1) gross margin from manufacturing efficiency and product mix, (2) selling, general & administrative expense discipline supported by established distributor and veterinary coverage, and (3) the ability to defend share through differentiated efficacy and label positioning. For animal health companies, margin durability often hinges on product life-cycle management (maximizing exclusivity windows), navigating competitive intensity, and maintaining stable supply operations.

🧠 Competitive Advantages & Market Positioning

Elanco’s moat is most defensible in the form of regulatory and commercialization barriers, plus switching costs created by installed protocols in veterinary and farm systems. While animal health lacks the same patent dynamics as human pharma in all cases, the overall barrier to entry remains elevated because competitors must clear substantial safety/efficacy testing and jurisdictional regulatory pathways to gain meaningful market access.

Additional structural advantages include:

  • High barriers to entry (regulatory + clinical evidence burden): Establishing label claims, demonstrating safety/efficacy, and building compliant manufacturing capacity are non-trivial and time-consuming.
  • Switching costs via practice protocols: Veterinary and producer decision-making is path-dependent; once outcomes are established, changing products can introduce operational risk.
  • Portfolio breadth and ecosystem effects: Cross-species commercial presence and multi-category offerings can improve penetration by serving multiple intervention points (prevention and treatment) with a single provider.

COMPETITIVE BENCHMARKING: Key competitors include Zoetis, Merck Animal Health (MSD), and VIRBAC. These firms compete across animal health segments but with different emphasis:

  • Zoetis often emphasizes scale and breadth across livestock and companion, leveraging strong global commercialization capabilities.
  • Merck Animal Health is known for a deep product base and strengths in specific therapeutic and prevention categories, supported by robust global infrastructure.
  • VIRBAC has a strong position in selected therapeutic areas, frequently reinforced by specialized offerings and veterinary channel relationships.

Elanco’s positioning leans on translating differentiated science into practical, protocol-driven products across multiple livestock and companion needs, aiming to defend utilization through efficacy-focused differentiation and continuity of supply.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth opportunities for animal health companies generally track structural demand rather than pure cyclicality. For Elanco, the main drivers include:

  • Protein demand and productivity imperatives: Efficient disease prevention and treatment support margins for livestock producers, sustaining demand for veterinary interventions even when feed and commodity conditions fluctuate.
  • Antiparasitic and antimicrobial stewardship pressures: Increased focus on responsible use and parasite resistance tends to increase the value of effective, properly labeled solutions and drives adoption of newer products or updated regimens.
  • Companion animal care as a structural category: Greater spend on preventive care and specialty treatment expands addressable opportunities outside purely livestock economics.
  • Pipeline-driven share gains: Growth is typically reinforced when new products extend portfolio relevance and replace declining assets, maintaining total category share in targeted endpoints.
  • Expanded access through distribution and veterinary coverage: Sustained execution in the field can raise utilization within existing customer bases, particularly when products address multiple intervention points.

⚠ Risk Factors to Monitor

  • Regulatory and approval execution risk: Delays or adverse findings in regulatory review can postpone commercialization or constrain label expansion.
  • Product life-cycle and competitive substitution: Patent/exclusivity windows can compress, and competitors may introduce superior efficacy, better safety profiles, or more favorable economics.
  • Resistance and efficacy variability: Parasite and pathogen evolution can reduce effectiveness of existing solutions, increasing the need for portfolio refresh.
  • Manufacturing and quality events: Animal health products require strict quality systems; disruptions can impair supply and credibility with vet channels.
  • Concentration in commercial channels and geographies: Distributor bargaining power and country-level purchasing behavior can influence pricing and volume stability.

📊 Valuation & Market View

Animal health equities are typically valued using a mix of EV/EBITDA and P/S, with investors often assigning premium multiples to businesses with credible product pipelines, stable gross margins, and improving capital efficiency. Where profitability is less mature, forward revenue quality (growth durability and mix) and operating leverage can matter as much as headline growth.

Key valuation drivers for the sector include:

  • Pipeline credibility and product life-cycle management (ability to offset declines with new launches)
  • Margin trajectory driven by mix, manufacturing efficiency, and competitive intensity
  • Share retention and utilization in established categories
  • Leverage and balance-sheet flexibility (capacity to invest through the cycle)

🔍 Investment Takeaway

Elanco’s long-term investment case rests on defensible barriers to entry in animal health, protocol-driven customer stickiness, and the compounding benefit of a broad portfolio that can serve multiple intervention needs across livestock and companion markets. The principal challenge is managing product life-cycles and competitive substitution while sustaining manufacturing reliability and pipeline execution—factors that tend to dominate intrinsic value creation in animal health over a multi-year horizon.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for ELAN.

youtube.com2026-06-04

Elanco CEO on rolling out New World screwworm vaccine: 'We're prepared'

Jeffrey Simmons, Elanco, joins 'Closing Bell Overtime' to talk producing a vaccine for the New World Screwworm infection in cattle in the U.S.

prnewswire.com2026-06-04

Elanco Animal Health Commits to Supporting U.S. Livestock Producers and Pet Owners in Fight Against New World Screwworm

Company offers portfolio of treatment options and expert guidance following first confirmed case in the United States  New World screwworm has officially reached the United States, with the first confirmed case in U.S. livestock in Texasi  New World screwworm can infest any warm-blooded animals – including livestock and pets – posing a significant threat to animal health, welfare, and producer livelihood  Elanco offers a portfolio of options for both livestock and pets that can treat infestations caused by New World screwworm larvae  INDIANAPOLIS , June 4, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today reaffirms its commitment to providing veterinarians, livestock producers, and pet owners with resources and treatment options for their animals against the escalating threat posed by New World screwworm (NWS). The fly recently reached the United States, with the first case confirmed in U.S. livestock in Texas.i  The emergence of New World screwworm in the U.S. creates a threat for veterinarians, livestock producers and pet owners that has not been seen north of the Florida Keys since the fly was eradicated from the United States more than 50 years ago.ii New World screwworm (Cochliomyia hominivorax) larvae feed on living tissue and can affect a wide range of warm-blooded animals, including livestock, companion animals, wildlife, and even humans.ii  "New World screwworm could have a devastating impact on animal health, welfare, and producer livelihoods," said Jeff Simmons, President and CEO, Elanco Animal Health.

benzinga.com2026-06-03

Jim Cramer Says He Feels 'Something Not Well' At Zoetis, Names A Rival As His Pick

On CNBC's “Mad Money Lightning Round,” Jim Cramer said about Zoetis Inc (NYSE:ZTS) that he feels "something not well there."

prnewswire.com2026-06-03

New Research Reveals Pet Spending as a "Protected Budget Item" for Owners, Fueling Industry Resilience

INDIANAPOLIS, June 3, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN), a global leader in animal health, today released new consumer research showing pet owners continue to prioritize spending on their pets, underscoring the robust and resilient nature of the industry. According to Elanco's latest survey of 1,409 U.S. pet owners conducted May 29-31, even with rising costs across spending categories including higher gas prices, pet health and wellness remain an absolute priority for pet owners as a protected budget item.

seekingalpha.com2026-06-02

Elanco Animal Health Incorporated (ELAN) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript

Elanco Animal Health Incorporated (ELAN) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript

seekingalpha.com2026-05-27

Elanco Animal Health Incorporated (ELAN) Presents at Stifel Jaws & Paws Conference 2026 Transcript

Elanco Animal Health Incorporated (ELAN) Presents at Stifel Jaws & Paws Conference 2026 Transcript

gurufocus.com2026-05-20

Is Elanco Animal Health Inc (ELAN) Overvalued After 5.3% Rally? GF Value Says Overvalued

On May 20, 2026, Elanco Animal Health Inc (ELAN) shares rose 5.3% today, closing at $20.85. This increase comes after a challenging month, where shares have dec

prnewswire.com2026-05-18

Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market

Phased launch of new anti-IL-31 monoclonal antibody is now underway, with product being used by select Early Experience Program veterinarians in clinics today Befrena is effective for the treatment of dogs against allergic dermatitis and canine atopic dermatitis with no age or weight restrictions, and lasts 6 to 8 weeks, compared to the 4 to 8 weeks of the current market incumbent, lokivetmab Starts controlling itch within 24 hours and is given as an in-clinic injection Select Early Experience Program veterinarians are already using Befrena in clinical practice and seeing positive outcomes Meet Beaux, Penelope and Zephyr, the first early experience patients to receive Befrena and follow their journeys to itch relief Befrena is Elanco's second monoclonal antibody to launch in the U.S. pet health market, joining Trutect™, the first and only approved therapeutic solution to treat canine parvovirus and has been shown to be effective for passive immunity INDIANAPOLIS, May 18, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the phased launch of Befrena™ (tirnovetmab), a new anti-IL-31 monoclonal antibody (mAb) injection for treatment of canine allergic and atopic dermatitis. The launch comes at a key time, with a longer and more intense allergy season anticipated across the country this year.i With nearly 2 in 3 itchy dogs experiencing worse itch during allergy seasonii, Befrena expands Elanco's dermatology portfolio by offering a new treatment option that starts controlling allergic itch within 24 hours.

gurufocus.com2026-05-15

Elanco Animal Health Inc (ELAN) Shares Fall 8.2% -- What GF Score of 70 Tells Investors

On May 15, 2026, Elanco Animal Health Inc (ELAN) shares fell 8.2% today, bringing the current price to $19.96. The stock has experienced considerable volatility

prnewswire.com2026-05-14

Elanco to Participate in Upcoming Investor Conferences

INDIANAPOLIS, May 14, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences. On Wednesday, May 27, Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will participate in a fireside chat at the Stifel 2026 Jaws & Paws Conference at 8:00 a.m.

marketbeat.com2026-05-10

Elanco Animal Health Q1 Earnings Call Highlights

Elanco Animal Health NYSE: ELAN raised its 2026 outlook after reporting stronger-than-expected first-quarter results, citing broad-based growth across pet health and farm animal businesses, accelerating demand for new products and continued debt reduction.

seekingalpha.com2026-05-06

Elanco Animal Health Incorporated (ELAN) Q1 2026 Earnings Call Transcript

Elanco Animal Health Incorporated (ELAN) Q1 2026 Earnings Call Transcript

youtube.com2026-05-06

'WE WILL BE PREPARED': Inside efforts to stop screwworm outbreak

Elanco Animal Health CEO Jeff Simmons discusses response to screwworm outbreak concerns on 'The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #theclamancountdown #elanco #animalhealth #jeffsimmons #screwworm #outbreak #health #animals #livestock #agriculture #farming #preparedness #biosecurity #veterinary #disease

benzinga.com2026-05-06

Elanco Animal Health Moves Higher On Earnings Strength And Product Momentum

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) are trading higher on Wednesday, following a recent announcement regarding the approval of its products, Negasunt Powder and Tanidil, which received emergency use authorization.

zacks.com2026-05-06

Elanco Animal Health Incorporated (ELAN) Beats Q1 Earnings and Revenue Estimates

Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.4 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.37 per share a year ago.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"ELAN reported Q1’26 revenue of $1.371B and net income of $57M (EPS $0.11), versus Q4’25 revenue of $1.144B and a net loss of $(276)M (EPS $(0.55)). QoQ, revenue rose +19.8% and net income turned sharply higher (from -$276M to +$57M). On a YoY basis, Q1’26 revenue was up +14.9% versus Q1’25 ($1.193B). Net income improved from $67M in Q1’25 to $57M in Q1’26 (YoY -14.9%). Profitability strengthened sequentially: gross margin expanded to 57.3% from 39.3% in Q4’25, and operating margin increased to 22.4% from 1.7%. However, profitability was down YoY (Q1’25 net margin 5.6% vs Q1’26 net margin 4.2%), suggesting earnings leverage is improving QoQ but not yet sustained vs last year’s comparable quarter. Cash flow quality deteriorated versus the strong Q3/Q2 periods: operating cash flow was $13M and free cash flow was -$38M, and cash decreased to $428M. Balance sheet leverage remained meaningful with total debt of $3.99B and net debt of $3.56B, but equity is stable and positive at $6.50B. For shareholder returns, ELAN showed very strong momentum with a +192.4% 1-year price change and no dividend. Total return is therefore likely driven by capital appreciation rather than cash yield. Analyst consensus targets imply upside to the current price (current $23.68 vs ~$28 consensus)."

Revenue Growth

Good

Q1’26 revenue of $1.371B rose +19.8% QoQ (vs Q4’25) and +14.9% YoY (vs Q1’25), indicating solid top-line momentum.

Profitability

Positive

Net income improved sharply QoQ (-$276M in Q4’25 to +$57M in Q1’26) and margins expanded sequentially (gross margin 39.3%→57.3%; operating margin 1.7%→22.4%). YoY profitability softened (net margin 5.6% in Q1’25 to 4.2% in Q1’26).

Cash Flow Quality

Fair

Operating cash flow was only $13M and free cash flow was -$38M in Q1’26, with cash declining $545M→$428M. This is weaker than prior quarters’ stronger cash generation.

Leverage & Balance Sheet

Positive

Net debt remains elevated at ~$3.56B (total debt ~$3.99B) and equity is positive at ~$6.50B. Balance sheet does not appear to be deteriorating dramatically QoQ, but leverage is still a constraint.

Shareholder Returns

Strong

Price momentum is very strong: +192.4% over 1 year. No dividend, and buybacks aren’t indicated in the provided cash flow, so returns are primarily from capital appreciation.

Analyst Sentiment & Valuation

Positive

Consensus price target is ~$28 vs current ~$23.68 (upside implied). Valuation multiples appear elevated (e.g., high P/E), so sentiment is constructive but risk remains if earnings quality lags.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Elanco’s Q1 2026 shows clear momentum behind the Big 6 innovation engine, with 10% organic constant-currency revenue growth and strong profitability (adjusted EBITDA +21% YoY, adjusted EPS +8%). The headline risk signal is cost: adjusted gross margin fell 40 bps to 57% due to inflation and inventory cost flow-through, but management expects 2H margin expansion as headwinds abate and U.S. Pet Health accelerates. Guidance was raised across the board: full-year organic growth to 5–7% and adjusted EPS to $1.03–$1.09, with adjusted EBITDA +$20M and improved end-of-year net leverage to 3.0x–3.2x. Operationally, Elanco Ascend is progressing quickly (>5,000 projects), and Zenrelia manufacturing moved to 24/7. In Q&A, management directly addressed U.S. early-quarter softness (cooler Jan–Feb) and confirmed corporate-account breadth via clinic pull. Zenrelia’s FDA label timing remains the key watch item, with additional data submission targeted by end of 2026.

AI IconGrowth Catalysts

  • Zenrelia market share gains with strong U.S. vet clinic sell-in; March growth 8% and April “even better” after Jan-Feb winter-storm disruption
  • Credelio Quattro accelerating dollar share gains: market share +3 points since Q4 and share +13 points in carrying clinics to 53% in Q1
  • Befrena phased launch momentum: shipped to early experience influencers; expected official launch in Q2 2026 with “orders in hand”
  • Robust U.S. OTC parasiticides momentum: new retailer additions (Costco, Dollar General) and double-digit dispensing growth at top retailers
  • International shipment timing: customer-driven accelerated shipments to the Middle East contributing ~1 percentage point to total-company growth
  • Farm animal growth led by Experior adoption (55% of U.S. Catalon feed using Experior) plus U.S. and international poultry/ruminant strength

Business Development

  • Retail partnerships/new customer wins: Costco and Dollar General (new customers flagged at December Investor Day)
  • Advantage family and Seresto distribution growth at top U.S. retailers (unnamed, but referenced as “top retailers”)
  • Acquisition: closing of AHV International acquisition on April 30, expanding share of voice in dairy
  • Manufacturing expansion partnerships/relationships implied via 24/7 manufacturing ramp to support rising Zenrelia demand (no named manufacturer referenced)
  • Bovaer demand tied to CPG companies supporting consistent count numbers (CPG partners not named)

AI IconFinancial Highlights

  • Reported revenue: $1.371B (+15% YoY reported); organic constant-currency revenue +10% (2% price, 8% volume)
  • Adjusted gross margin: 57%, down 40 bps YoY (inventory cost and inflation pressures cited); expected meaningful expansion in 2H as inventory headwinds pass
  • Adjusted EBITDA: $334M (+$58M, +21% YoY)
  • Adjusted EPS: $0.40 (+8% YoY); EPS benefited from lapping favorable one-time tax benefits in the prior year
  • Q1 drove guidance raise: full-year organic constant-currency revenue 5% to 7% (from 4% to 6%); adjusted EBITDA increased by $20M; adjusted EPS increased by $0.03 to $1.03–$1.09
  • Net leverage: 3.5x at quarter-end; full-year target improved to 3.0x–3.2x (from 3.1x–3.3x)

AI IconCapital Funding

  • Net debt: $3.3B at quarter-end; paydown remains primary use of free cash flow with long-term target 2.0x–2.5x
  • No explicit buyback amount disclosed in transcript
  • Expectation to reach below 3x net leverage next year (greater capital allocation flexibility)

AI IconStrategy & Ops

  • Elanco Ascend productivity program: >5,000 projects logged; 75% of savings expected in gross margin with near-term benefits in G&A (from prior restructuring)
  • Automation/AI integration across value chain; example implemented automated sales order tool modernizing order-to-cash to improve fulfillment accuracy, accelerate order cycles, and lower operational costs
  • Manufacturing capacity expansion for Zenrelia; production moved to 24/7 to support rising global demand entering derm season
  • Pricing actions: price +2% in Q1; implemented largest price increase in 5 years to U.S. fat clinics
  • Launch strategy: “no regress launch approach” for Big 6; Befrena phased launch typical for MAB scale-up

AI IconMarket Outlook

  • Full-year guidance: organic constant-currency revenue 5%–7%, adjusted EBITDA $975M–$1.005B, adjusted EPS $1.03–$1.09
  • Full-year reported revenue range raised to $5.01B–$5.085B; includes ~$60M FX tailwind (captured majority in Q1)
  • End-of-year net leverage updated to 3.0x–3.2x
  • Q2 guidance: reported revenue $1.3B–$1.325B; organic constant-currency growth 4%–6%; adjusted EBITDA $240M–$260M; adjusted EPS $0.25–$0.28
  • U.S. Pet Health back-half acceleration expectation: high single-digit to low double-digit growth; full-year U.S. Pet Health expected at least high single-digit growth (not contingent on improved vet visit volumes)
  • Zenrelia FDA timing: additional study expected to be submitted by end of 2026

AI IconRisks & Headwinds

  • Gross margin headwind: 40 bps YoY decline in Q1 from inflation and inventory cost flow-through; mix pressure cited (Farm Animal strength partly offset)
  • Competitive pressures: “heightened competitive pressures, including generics” could push results toward lower end of guided ranges
  • Consumer-level economic shifts as potential headwind
  • Farm Animal growth normalization: U.S. Farm Animal expected to normalize to long-term algorithm; harder year-over-year comparisons ahead
  • Guidance sensitivity to external scenarios acknowledged (could shift to lower or higher end depending on macro, Ascend progress, and launch investments)

Q&A: Analyst Interest

  • Topic: U.S. Pet Health softness early in Q1 and what changed for acceleration. Management attributed January/February weakness to cooler temperatures and industry-wide winter storm seasonality, then emphasized a rebound: March +8% and April “even better,” with Zenrelia and Quattro strength, Befrena launch contributions, and retail distribution/omnichannel momentum.
  • Topic: Corporate account commitments—whether competitive wins and how broad-based. Management said corporate accounts were previously under-indexed, with a 12% step-up (double the growth rate vs prior year). They framed wins as pull from clinic adoption (Zenrelia >50% of clinics; Quattro ~40% carrying) using value-based approaches to avoid price erosion.
  • Topic: Zenrelia success despite FDA label restrictions and timing for label improvement. Management emphasized efficacy and demand: 24/7 manufacturing ramp, over 50% U.S. clinic presence, ~2M dogs treated, and global traction (44+ countries, labels without restrictions). FDA requested additional research; management expects submission of additional data by end of 2026.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the ELAN Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for ELAN.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (ELAN)

© 2026 Stock Market Info — Elanco Animal Health Incorporated (ELAN) Financial Profile